Literature DB >> 11012188

Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention.

J L Nichol1.   

Abstract

The factor which is the primary regulator of megakaryocyte and platelet production has recently been identified as the ligand for the receptor Mpl. This discovery has resulted in substantial advances in our understanding of platelet homeostasis. The access to new experimental reagents has enabled studies of the endogenous circulating form of this ligand, endogenous thrombopoietin, in normal individuals and in patients with altered platelet numbers. The relationship of endogenous TPO in health and disease will be examined with consideration of the implications for successful therapeutic intervention with exogenous recombinant Mpl ligands in selected settings.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11012188     DOI: 10.1002/stem.5530160719

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  11 in total

Review 1.  Eltrombopag-based combination treatment for immune thrombocytopenia.

Authors:  David Gómez-Almaguer
Journal:  Ther Adv Hematol       Date:  2018-10-04

2.  [Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].

Authors:  Ingrid Pabinger; Günther Gastl; Michael Steurer; Siegfried Sormann; Michael Fillitz; Josef Friedl; Dietmar Geissler; Klaus Geissler; Richard Greil; Paul Knöbl; Sibylle Kozek-Langenecker; Peter Krippl; Paul Kyrle; Alois Lang; Werner Linkesch; Heinz Ludwig; Markus Müller; Simon Panzer; Elisabeth Pittermann; Josef Thaler; Ansgar Weltermann
Journal:  Wien Klin Wochenschr       Date:  2012-03-03       Impact factor: 1.704

3.  Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists.

Authors:  Oliver Meyer; Eric Herzig; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2011-12-23       Impact factor: 3.747

Review 4.  Immune thrombocytopenia.

Authors:  Gaurav Kistangari; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2013-06       Impact factor: 3.722

Review 5.  The Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and Pathogenesis.

Authors:  Rita Consolini; Annalisa Legitimo; Maria Costanza Caparello
Journal:  Front Pediatr       Date:  2016-10-19       Impact factor: 3.418

6.  Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias.

Authors:  F L B Ferreira; M P Colella; S S Medina; C Costa-Lima; M M L Fiusa; L N G Costa; F A Orsi; J M Annichino-Bizzacchi; K Y Fertrin; M F P Gilberti; M C Ozelo; E V De Paula
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

7.  Treatment of immune thrombocytopenic purpura: focus on eltrombopag.

Authors:  Lawrence Rice
Journal:  Biologics       Date:  2009-07-13

Review 8.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

Review 9.  Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia.

Authors:  Angelica Maria Garzon; William Beau Mitchell
Journal:  Front Pediatr       Date:  2015-08-13       Impact factor: 3.418

10.  Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy.

Authors:  Xu Zhang; Yajing Zhao; Xiaoqing Li; Panpan Han; Fangmiao Jing; Zhangyuan Kong; Hai Zhou; Jihua Qiu; Lizhen Li; Jun Peng; Ming Hou
Journal:  Oncotarget       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.